Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Jumpcode Genomics Inc. manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently has 2 pending office actions. The management of these 2 pending office actions requires coordination across multiple examiners. These actions are distributed across 2 distinct examiners, indicating a diversified examination process for the pending applications. This distribution of 2 distinct examiners represents a more complex prosecution environment than the 1 pending office action assigned to the busiest examiner.
The prosecution activity spans 2 distinct art units, which suggests the portfolio covers multiple technical sub-sectors. BERTAGNA, ANGELA MARIE is identified as the busiest examiner for the portfolio and is responsible for 1 pending office action. This 1 pending office action is currently assigned to the busiest examiner while the remaining workload is handled elsewhere. For the company, this requires a management strategy to ensure consistency across the different technical groups involved in the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18163196 | CAPTURE OF NUCLEIC ACIDS USING A NUCLEIC ACID-GUIDED NUCLEASE-BASED SYSTEM | BERTAGNA, ANGELA MARIE | — |
| 17761866 | METHOD AND SYSTEM FOR TARGETED NUCLEIC ACID SEQUENCING | GUSSOW, ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18163196 | CAPTURE OF NUCLEIC ACIDS USING A NUCLEIC ACID-GUIDED NUCLEASE-BASED SYSTEM | BERTAGNA, ANGELA MARIE | — |
| 17761866 | METHOD AND SYSTEM FOR TARGETED NUCLEIC ACID SEQUENCING | GUSSOW, ANNE | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18163196 | CAPTURE OF NUCLEIC ACIDS USING A NUCLEIC ACID-GUIDED NUCLEASE-BASED SYSTEM | BERTAGNA, ANGELA MARIE | 1681 | §103§112 | Non-Final OA | — | Pending | Feb 01, 2023 |
| 17761866 | METHOD AND SYSTEM FOR TARGETED NUCLEIC ACID SEQUENCING | GUSSOW, ANNE | 1600 | §102§103§112 | Final Rejection | — | Pending | Mar 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial